source
- Enveda Biosciences raises $311 million in Series E to accelerate nature-derived drug developmentEnveda Biosciences announced a $311 million Series E financing round, adding to the more than $500 million it has raised in previous rounds. The new capital follows a $130 million Series C in Nove…
- Kyverna reports year-long efficacy and clean safety for miv-cel CAR-T in autoimmune trialsKyverna Therapeutics released one-year data for its CAR-T candidate miv-cel in stiff person syndrome and 18-month data in generalized myasthenia gravis. The single dose showed durable clinical ben…